Is Arca Biopharma Inc (ABIO) Stock About to Get Hot Wednesday?

Overall market sentiment has been high on Arca Biopharma Inc (ABIO) stock lately. ABIO receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Arca Biopharma Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ABIO!

See Full ABIO Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ABIO Stock Today?

Arca Biopharma Inc (ABIO) stock is trading at $2.10 as of 2:40 PM on Wednesday, Nov 23, an increase of $0.02, or 0.96% from the previous closing price of $2.08. The stock has traded between $2.06 and $2.12 so far today. Volume today is light. So far 8,048 shares have traded compared to average volume of 22,632 shares.

More About Arca Biopharma Inc

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Click Here to get the full Stock Report for Arca Biopharma Inc stock.